Willingness to pay for avoiding coronary restenosis and repeat revascularization: Results from a contingent valuation study

Health Policy

Volumn 70, Issue 2, 2004, Pages 207-216

  Greenberg, Dan ^a,b,c,d   Bakhai, Ameet ^a,b,c,e   Neumann, Peter J ^d   Cohen, David J ^a,b,c,d  

^a HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Contingent valuation; Drug eluting stents; Percutaneous coronary intervention (PCI); Restenosis; Willingness to pay

Indexed keywords

ADULT; AGED; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEVICE; DRUG ELUTING STENT; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PARAMETER; PERCUTANEOUS CORONARY INTERVENTION; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVASCULARIZATION; RISK ASSESSMENT; RISK REDUCTION;

AGED; CORONARY RESTENOSIS; FEMALE; FINANCING, PERSONAL; HEALTH SERVICES RESEARCH; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION;

EID: 4444267310     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healthpol.2004.03.002     Document Type: Conference Paper

References (54)

1. Sapirstein W., Zuckerman B., Dillard J. FDA approval of coronary-artery brachytherapy. New England Journal of Medicine. 344(4):2001;297-299
2. Fischman D.L., Leon M.B., Baim D.S., Schatz R.A., Savage M.P., Penn I.M., et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. New England Journal of Medicine. 331(8):1994;496-501
3. Serruys P.W., de Jaegere P., Kiemeneij F., Macaya C., Rutsch W., Heyndrickx G., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent study group. New England Journal of Medicine. 331(8):1994;489-495
4. Rankin J.M., Spinelli J.J., Carere R.G., Ricci D.R., Penn Im., Hilton J.D., et al. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. New England Journal of Medicine. 341(26):1999;1957-1965
5. Serruys P.W., van Hout B., Bonnier H., Legrand V., Garcia E., Makaya C., et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent, II). Lancet. 352(9129):1998;673-681
6. Williams D.O., Holubkov R., Yeh W., Bourassa M.G., Al-Bassam M., Block P.C., et al. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation. 102(24):2000;2945-2951
7. Cohen D.J., Becker E.R., Culler S.D., Allis S., Green L.M., Schnitzler R.N., et al. Impact of patient characteristics, complications, and facility volume on the costs and time of cardiac catheterization, coronary angioplasty, and stenting in 70 catheterization laboratories. American Journal of Cardiology. 86(6):2000;595-601
8. Sousa J.E., Costa M.A., Abizaid A.C., Rensing B.J., Abizaid A.S., Tanajura L.F., et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents. One year angiographic and intravascular ultrasound follow-up. Circulation. 104:2001;2007-2011
9. Leon M.B., Teirstein P.S., Moses J.W., Tripuraneni P., Lansky A.J., Jani S., et al. Localized intracoronary gamma radiation therapy to inhibit the recurrence of restenosis after stenting. M. Engl. J. Med. 344(4):2001;250-256
10. Morice M.C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., et al. A randomized comparison of sirolimus-eluting stent with standard stent for coronary revascularization. New England Journal of Medicine. 343(23):2002;0773-0780
11. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. New England Journal of Medicine. 349(14):2003;1315-1323
12. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. New England Journal of Medicine. 350(3):2004;221-231
13. Greenberg D., Bakhai A., Cohen D.J. Can we afford to eliminate restenosis? Can we afford not to? Journal of the American College of Cardiology. 43(4):2004;513-518
14. Doubilet P., Weinstein M.C., McNeil B.J. Use and misuse of the term "cost effective" in medicine. New England Journal of Medicine. 314(4):1986;253-256
15. Gold M, Siegel J, Russel L, Weinstein M, editors. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press, 1996.
16. Weintraub W.S., Ghazzal Z.M., Douglas J.S. Jr., Liberman H.A., Morris D.C., Cohen C.L., et al. Long-term clinical follow-up in patients with angiographic restudy after successful angioplasty. Circulation. 87(3):1993;831-840
17. Rinfret S., Grines C.L., Cosgrove R.S., Ho K.K., Cox D.A., Brodie B.R., et al. Quality of life after balloon angioplasty or stenting for acute myocardial infarction. One-year results from the Stent-PAMI trial. Journal of the American College of Cardiology. 38(6):2001;1614-1621
18. Weaver W.D., Reisman M.A., Griffin J.J., Buller C.E., Leimgruber P.P., Henry T., et al. Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trial. Lancet. 355(9222):2000;2199-2203
19. Serruys P.W., Unger F., Sousa J.E., Jatene A., Bonnier H.J., Schonberger J.P., et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. New England Journal of Medicine. 344(15):2001;1117-1124
20. Cohen D.J., Taira D.A., Berezin R., Cox D.A., Morice M.C., Stone G.W., et al. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the stent primary angioplasty in myocardial infarction (stent-PAMI) trial. Circulation. 104(25):2001;3039-3045
21. Cohen D.J., Cosgrove R.S., Berezin R.H., Teirstein P.S., Leon M.B., Kuntz R.E. Cost-effectiveness of gamma radiation for treatment of in-stent restenosis: results from the Gamma-1 trial. Circulation. 106:2002;691-697
22. O'Brien B., Gafni A. When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care. Medical Decision Making. 16(3):1996;288-299
23. Olsen J.A., Smith R.D. Theory versus practice: a review in 'willingness-to-pay' in health and health care. Health Economics. 10(1):2001;39-52
24. Donaldson C. Eliciting patients' values by use of 'willingness to pay': letting the theory drive the method. Health Expectations. 4:2001;180-188
25. Klose T. The contingent valuation method in health care. Health Policy. 47(2):1999;97-123
26. Smith R.D. Construction of the contingent valuation market in health care: a critical assessment. Health Economics. 12(8):2003;609-628
27. Diener A., O'Brien B., Gafni A. Health care contingent valuation studies: a review and classification of the literature. Health Economics. 7(4):1998;313-326
28. Kartman B., Andersson F., Johannesson M. Willingness to pay for reduction in angina pectoris attacks. Medical Decision Making. 16:1996;248-253
29. Baim D.S., Cutlip D.E., Sharma S.K., Ho K.K., Fortuna R., Schreiber T.L., et al. Final results of the Balloon vs. Optimal Atherectomy Trial (BOAT). Circulation. 97(4):1998;322-331
30. Baim D.S., Cutlip D.E., Midei M., Linnemeier T.J., Schriber T., Cox D., et al. Final results of a randomized trial comparing the MULTI-LINK stent with the Palmaz-Schatz stent for narrowings in native coronary arteries. American Journal of Cardiology. 87(2):2001;157-162
31. Administration, NOAA, Report of the NOAA Panel on Contingent Valuation. Fed Reg 1993;58:4607-14.
32. Johannesson M., Jonsson B., Karlsson G. Outcome measurement in economic evaluation. Health Economics. 5(4):1996;279-296
33. Blumenschein K., Johannesson M., Yokoyama K.K., Freeman P.R. Hypothetical versus real willingness to pay in the health care sector: results from a field experiment. Journal of Health Economics. 20(3):2001;441-457
34. Nino C.L., Freed M., Blankenship L., Grines C.L., O'Neill W.W., Safian R.D. Procedural cost of new interventional devices. American Journal of Cardiology. 74(11):1994;1165-1166
35. Johannesson M., Liljas B., Johansson P.O. An experimental comparison of dichotomous choice contingent valuation questions and real purchase decisions. Applied Economics. 30:1998;643-647
36. Kriström B. A non-parametric approach to the estimation of welfare measures in discrete response valuation studies. Land Economics. 66(2):1990;135-139
37. Hanemann M.W. Welfare evaluations in contingent valuations experiments with discrete responses. American Journal of Agricultural Economics. 66:1984;332
38. Hammitt J.K., Graham J.D. Willingness to pay for health protection: inadequate sensitivity to probability. Journal of Risk Uncertainty. 8:1999;33-62
39. Anderson H.V., Shaw R.E., Brindis R.G., Hewitt K., Krone R.J., Block P., et al. A contemporary overview of percutaneous coronary interventions. The American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). Journal of the American College of Cardiology. 39(7):2002;1096-1103
40. Olsen J.A. Aiding priority setting in health care: is there a role for the contingent valuation method. Health Economics. 6(6):1997;603-612
41. Bala M.V., Zarkin G.A. Are QALYs an appropriate measure for valuing morbidity in acute diseases. Health Economics. 9(2):2000;177-180
42. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. New York: Oxford University Press, 1997.
43. Office of Management and Budget. Draft 2003 Report to Congress on the Costs and Benefits of Federal Regulations Notice. Fed Reg 2003;68:5492-527.
44. Marbro K., Sjostrom L. Willingness to pay for obesity treatment. International Journal of Technology Assessment in Health Care. 16(1):2000;50-59
45. Cross M.J., March L.M., Lapsley H.M., Tribe K.L., Bmabic A.J., Courtenay B.G., et al. Determinants of willingness to pay for hip and knee joint replacement surgery for osteoarthritis. Rheumatology. 39(11):2000;1242-1248
46. Johannesson M., O'Conor R.M., Kobelt-Nguyen G., Mattiasson A. Willingness to pay for reduced incontinence symptoms. British Journal of Urology. 80(4):1997;557-562
47. Ramsey S.D., Sullivan S.D., Psaty B.M., Patrick D.L. Willingness to pay for antihypertensive care: evidence from a staff-model HMO. Social Science and Medicine. 44(12):1997;1911-1917
48. Lee S.J., Neumann P.J., Hallowell C., Cannon M.E., Weinstein M.C., Johannesson M. Patients' willingness to pay for autologous blood donation. Health Policy. 40(1):1997;1-12
49. Kahneman D., Tversky A. Prospect theory: an analysis of decision under risk. Econometrica. 47(2):1979;263-292
50. Johannesson M. A note on the relationship between ex ante and expected willingness to pay for health care. Social Science and Medicine. 42(3):1996;305-311
51. Smith R.D. The discrete-choice willingness-to-pay question format in health economics: should we adopt environmental guidelines. Medical Decision Making. 20(2):2000;194-206
52. Whynes D.K., Frew E., Wolstenholme J.L. A comparison of two methods for eliciting contingent valuations of colorectal cancer screening. Journal Health Economics. 22(4):2003;555-574
53. Frew E.J., Whynes D.K., Wolstenholme J.L. Eliciting willingness to pay: comparing closed-ended with open-ended and payment scale formats. Medical Decision Making. 23(2):2003;150-159
54. Drummond M. Introducing economic and quality of life measurements into clinical studies. Annals of Medicine. 33(5):2001;344-349